Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Groupe Oncologie Radiotherapie Tete et Cou clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our France register with Groupe Oncologie Radiotherapie Tete et Cou as lead sponsor. Synced 17 Nov 2026
9Current trials
4Recruiting now
17Drugs in these trials
1Trial register
At a glance

Groupe Oncologie Radiotherapie Tete et Cou is the lead sponsor of 9 current clinical trials in our France register. 4 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Cisplatin, Cetuximab and Nivolumab. The most-studied condition is HNSCC.

ClinicalTrials.gov trials by status

  • Recruiting444%
  • Active, closed556%

Trials by phase

  • Phase 3556%
  • Phase 2444%
01

Clinical trials sponsored by Groupe Oncologie Radiotherapie Tete et Cou

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
NCT06959108 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting 2025-10 France
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Phase 3 Recruiting 2026-05 France
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
NCT06640725 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Phase 2 Recruiting 2025-01 France
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
NCT07529873 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 2 Recruiting 2026-03 France
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
NCT02999087 · ClinicalTrials.gov ↗ · HNSCC
Phase 3 Active, closed 2017-09 France
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
NCT03070366 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
Phase 2 Active, closed 2015-09 France
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
NCT03576417 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck
Phase 3 Active, closed 2018-10 France
Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)
NCT02998385 · ClinicalTrials.gov ↗ · HNSCC
Drug: Cisplatin
Phase 3 Active, closed 2017-01 France
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
NCT03340896 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
Phase 3 Active, closed 2015-06 France

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Groupe Oncologie Radiotherapie Tete et Cou trials

17 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Groupe Oncologie Radiotherapie Tete et Cou trials

7 conditions
HNSCC2Head and Neck Squamous Cell Carcinoma2Locally Advanced Head and Neck Squamous Cell Carcinoma1Squamous Cell Carcinoma of Head and Neck1Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)1Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck1Squamous Cell Carcinoma of Head and Neck (SCCHN)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in France94

A trial with sites in more than one country appears in each of those registers.

05

Questions about Groupe Oncologie Radiotherapie Tete et Cou trials

How many clinical trials does Groupe Oncologie Radiotherapie Tete et Cou sponsor?

Groupe Oncologie Radiotherapie Tete et Cou is the lead sponsor of 9 current trials on ClinicalTrials.gov in our France register, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Groupe Oncologie Radiotherapie Tete et Cou trials recruiting?

Yes. 4 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Groupe Oncologie Radiotherapie Tete et Cou testing?

Its current trials name 17 drugs and biologicals as interventions. The most frequent are Cisplatin (4), Cetuximab (2), Nivolumab (2), Adrucil (1) and Avelumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.